By continuing to use the site you agree to our Privacy & Cookies policy

Lung cancer drugs erlotinib and gefitinib under review by NICE

The National Institute for Health and Care Excellence is reviewing its guidance on the use of two lung cancer drugs – erlotinib and gefitinib – in response to changing clinical practice.

Get unlimited access

As a subscriber you will benefit from:

  • Full online and mobile access to news and opinion stories
  • Customised email alerts straight to your inbox (over 30 alerts available)
  • 4,500 practice articles in our archive 
  • Over £500 worth of CPD learning units